Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > I wonder what this means?

<< Previous

Bullboard Posts

Next >>

Comment by Spartrapon Feb 10, 2021 9:36am

110 Views

Post# 32523579

RE:I wonder what this means?

It does read like a flat out rejection of both drugs to me. ;-/
Now that they are not longer part of the EU, they are freeer to reject costly efficacious drugs and just let MDR HIV patients die instead.
Good for them!

qwerty22 wrote:
NICE is the UKs assessment system for drugs to be used in the NHS. Looks like both fostemsavir and Trogarzo are going thru the process together. They both got the same outcome from a Nov 2020 meeting.

"Oversight Panel concluded that an appraisal of ibalizumab in combination with other antiretroviral treatment for multidrug-resistant HIV-1 would be of limited value to the NHS at this time and therefore the topic will not progress any further"

It sounds pretty negative but I can't believe both drugs are being blocked for use in the NHS so it must just mean there is nothing to be gained from further talking. What you think? Could there be a UK decision soon? Be interesting if both drugs become available together. Might we get a culture of double switching in UK?

https://www.nice.org.uk/guidance/proposed/gid-ta10657

https://www.nice.org.uk/guidance/proposed/gid-ta10605